CorMedix (CRMD) Stock Forecast & Price Target

Cormedix Inc. reports strong utilization and patient growth for its product, DefenCath, particularly among outpatient dialysis customers, indicating a robust market demand. The company projects a significant improvement in DefenCath's pricing, anticipating sales of $100 million to $140 million in 2027, which reflects the positive impact of real-world evidence demonstrating a 72% reduction in catheter-related bloodstream infections and associated hospitalizations among patients. Additionally, potential cost savings for healthcare systems, along with further uptake and evaluation of secondary endpoints, could further enhance the economic value of DefenCath and contribute to an optimistic financial outlook for the company.

Cormedix Inc. has issued guidance for 2026 that significantly underperforms market expectations, projecting revenue of $300 million to $320 million, while consensus estimates stand at $423 million, indicating potential challenges in meeting growth targets. This negative outlook is amplified by the anticipated revenue drop for DefenCath after the transition to a standard post-TDAPA Add-On Adjustment, which is expected to reduce pricing and reimbursement rates in the latter half of 2026. Furthermore, the competition from generics like Heparin may hinder DefenCath's market performance, raising concerns about the company's ability to maintain growth in catheter lock solution sales.